SOLVING KIDS CANCER INC
1 EAST 53RD STREET 5TH FLOOR, NEW YORK, NY 10022 www.solvingkidscancer.org

---

Organizations Filed Purposes: SKC IMPACTS CHILDREN THROUGH THE INITIATION OF CLINICAL RESEARCH TRIALS OF INVESTIGATIONAL TREATMENT STRATEGIES. OUR VISION IS TO CONTINUE EXPANDING THE ARMAMENTARIUM OF EFFECTIVE AND LESS TOXIC TREATMENT STRATEGIES FOR PEDIATRIC ONCOLOGISTS TO UTILIZE UNTIL LONG-TERM SURVIVAL IS A REALITY FOR ALL CHILDREN WITH HIGH-RISK SOLID TUMORS AND BRAIN TUMORS.TO ACCOMPLISH OUR MISSION, SOLVING KIDS' CANCER FINDS, FUNDS AND ADVOCATES FOR BREAKTHROUGH TREATMENT OPTIONS TO CURE CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS THROUGH COLLABORATIVE PARTNERSHIPS WITH THE RESEARCH COMMUNITY AND RELATED NONPROFIT STAKEHOLDERS.

MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS USING A PATIENT-CENTRIC APPROACH OF DRIVING/SUPPORTING HIGH-IMPACT CLINICAL RESEARCH, CONDUCTING RESEARCH ADVOCACY IN THE LANDSCAPE AND EMPOWERING FAMILIES WITH RESOURCES/TOOLS TO HELP THEM NAVIGATE TREATMENT FOR THEIR CHILD.

SKC AND ITS ADVISORS SURVEY THE PEDIATRIC CANCER LANDSCAPE TO UNDERSTAND AND PRIORITIZE THE GREATEST UNMET NEEDS OF PATIENTS AND DEVELOPS AND FUNDS PROGRAMS TO ADDRESS THEM. (1) SKC TAKES A GLOBAL APPROACH TO OUR PROGRAMS RATHER THAN LOCAL, TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (2) PRIORITIZES AND FOCUSES ON MOST FATAL CHILDHOOD CANCER TYPES WITH <50% SURVIVAL INCLUDING HIGH RISK SOLID TUMORS AND BRAIN TUMORS. (3) DIRECTS RESEARCH FUNDING AND PROGRAMS TO THE FRONTLINES OF IMPACTING CHILDREN CLINICAL TRIALS AND DEVELOPING NEW TREATMENTS. (4) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE.SURVIVAL RATES REMAIN UNSATISFACTORILY LOW FOR THE DEADLIEST CHILDHOOD CANCERS WHILE DECADES-OLD MODALITIES LIKE CHEMOTHERAPY AND RADIATION REMAIN THE PROMINENT STANDARDS-OF-CARE AND ARE NOT CURATIVE FOR NEARLY HALF OF HIGH-RISK PATIENTS. SKC FOCUSES ON ADVANCING NOVEL AGENTS/COMBINATIONS IN ALL PHASES OF THE TREATMENT SPECTRUM WITH THE HIGHEST CURATIVE RATIONALE, STARTING IN CHILDREN WITH RELAPSE/REFRACTORY DISEASE, WITH A GOAL TO MOVE INTO FRONTLINE TREATMENT REGIMENS FOR NEWLY DIAGNOSED CHILDREN ESTABLISHING A GOLD STANDARD-OF-CARE IN A PERSONALIZED APPROACH PROVIDING THE RIGHT TREATMENTS TO THE RIGHT PATIENTS.SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. SKC HAS SUPPORTED 27 CLINICAL TRIALS RESULTING IN 25 NEW EXPERIMENTAL TREATMENT OPTIONS FOR CHILDREN WITH HIGH-RISK CANCERS AND 10 PRECLINICAL DEVELOPMENT PROJECTS.OUR MOST RECENT PROGRAMS INCLUDE THE DEVELOPMENT OF A NEW IMMUNOTHERAPY CONSTRUCT AGAINST A NEWLY DISCOVERED TARGET IN NEUROBLASTOMA, MEDULLOBLASTOMA AND ETMR; PROJECTS TO ADVANCE A GENOMICALLY TARGETED THERAPEUTIC AGAINST ALK AND ANOTHER TO ADVANCE A COMBINATION THERAPY AGAINSTS POLYAMINES INTO FRONTLINE TREATMENT PROTOCOLS FOR NEUROBLASTOMA; A FIRST-EVER LARGE SCALE SINGLE-CELL GENOMIC SEQUENCING OF ETMR TUMORS TO SHED UNPRECEDENTED LIGHT ON TUMOR CELLULAR ARCHITECTURE AND COMPOSITION NOT POSSIBLE BY BULK TUMOR ANALYSES ALLOWING THE IDENTIFICATION OF ALL CELL-TYPES IN PATIENT TUMORS IN AN UNBIASED FASHION; THE ESTABLISHMENT OF A NEW PLATFORM FOR TESTING A MENU OF THERAPEUTIC OPTIONS TO INFORM SUBSEQUENT TREATMENT CHILDREN WITH MEDULLOBLASTOMA USING ORGANOTYPIC SLICE CULTURES.

---

---

Data for this page was sourced from XML published by IRS (public 990 form dataset) from: https://s3.amazonaws.com/irs-form-990/202012949349301516_public.xml